Key result
Tumor MPL mRNA levels are very low or undetectable compared to EPOR, ERBB2, and IGF1R.
Why the study?
There are concerns that use of certain growth factors can hasten disease progression in some hematologic malignancies and solid tumors, motivating examination of TPO receptor expression in tumors.
TPO-R agonists are unlikely to stimulate tumor progression in the studied cancers due to very low or undetectable MPL mRNA expression.
May inform TPO-R agonist safety in oncology; hypothesis-generating and requires prospective human validation.
Thrombopoietin (TPO) receptor agonists represent a new approach for the treatment of thrombocytopenia, which may develop as a consequence of immune thrombocytopenia, chemotherapy treatment, chronic hepatitis C infection, or myelodysplastic syndromes. There are concerns that use of certain growth factors can hasten disease progression in some types of hematologic malignancies and solid tumors. In this study, expression of MPL (TPO-R) mRNA was examined in tumor cell lines, patient tumor samples (renal cell carcinoma, prostatic carcinoma, soft tissue and bony/cartilage sarcoma, colon cancer, and lymphoma), and normal tissues using microarray analysis and qRT-PCR. MPL mRNA is expressed at very low or undetectable levels compared with erythropoietin receptor (EPOR), human epidermal growth factor (ERBB2; HER2), and insulin-like growth factor-1 receptor (IGF1R) in these patient samples. These data suggest TPO-R agonists will likely preferentially stimulate proliferation and differentiation of cells of megakaryocytic lineage, potentially demonstrating their utility for correcting thrombocytopenia in clinical settings.
No takes yet. Share an insight, caveat, or question.
Erickson‐Miller et al. (2010) studied Tumors (renal cell carcinoma, prostatic carcinoma, sarcoma, colon cancer, lymphoma). MPL (TPO-R) mRNA expression vs. EPOR, ERBB2, and IGF1R expression was evaluated on MPL (TPO-R) mRNA expression levels. MPL (TPO-R) mRNA is expressed at very low or undetectable levels in tumor cell lines and patient tumor samples compared with EPOR, ERBB2, and IGF1R.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: